Impact of Prefrontal Cortex in Nicotine-Induced Excitation of Ventral Tegmental Area Dopamine Neurons in Anesthetized Rats

Die Zhang, Ming Gao, Dan Xu, Wei-Xing Shi, Boris S. Gutkin, Scott C. Steffensen, Ronald J. Lukas, and Jie Wu

Introduction

The mammalian ventral tegmental area (VTA) (A10) is a midbrain region long implicated as an integrative center mediating incentive and motivational effects for almost all addictive drugs including nicotine. Within the VTA, dopamine (DA) neurons and their associated ascending projections to the nucleus accumbens (NAC) and medial prefrontal cortex (mPFC) comprise the well-characterized mesolimbic and mesocortical pathways, respectively. It has been reported that VTA DA neurons receive glutamatergic inputs directly or indirectly from the PFC (Kalivas, 1993; Charara et al., 1996; Carr and Sesack, 2000; Omelchenko and Sesack, 2007) and other brain regions (Geisler and Wise, 2008). In addition, the VTA receives cholinergic projections from the laterodorsal tegmental nucleus (Garzón et al., 1999). Although effects must occur via different molecular mechanisms of action and perhaps through different neuronal circuits, increases in VTA DA neuronal firing and in DA release in the NAc and PFC have been proposed to be a common mechanism underlying dependence on addictive drugs (Mathon et al., 2003).

Our current understanding of the mechanisms underlying nicotine-induced excitation of VTA DA neurons is based on studies done using brain slices (Dani and Heinemann, 1996; Mansvelder and McGehee, 2000; Mansvelder and McGehee, 2002). However, the interaction between the VTA and other brain regions is interrupted in brain slices, studies in a more intact in vivo system are needed. Emerging evidence demonstrates that the mPFC plays an important role in controlling VTA DA neuronal function (Mansvelder et al., 2009). The mPFC contributes to cognitive processes, such as attention, spatial learning, behavioral...
planning, and working memory (Fuster, 2000). Nicotine has been reported to act through nicotinic acetylcholine receptors (nAChRs) in the PFC to enhance working memory and attention (Levin, 1992; Granon et al., 1995; Levin et al., 2006; Counotte et al., 2011; Guillem et al., 2011). In addition, the mPFC has been suggested to be a key brain region underlying neural mechanisms of drug addiction and craving (Tschenkente, 2001).

Functionally, the mPFC and VTA have been shown to be closely coupled (Peters et al., 2004; Gao et al., 2007). Stimulation of the mPFC increases burst firing in VTA DA neurons, whereas disruption of signaling from the PFC induces the opposite effect (Gariano and Groves, 1988; Svensson and Tung, 1989; Murase et al., 1993; Overton et al., 1996a; Tong et al., 1996). We reported previously that, under nonstimulation conditions, VTA DA neurons exhibit robust oscillatory activity (0.5–1.5 Hz) in anesthetized rats (Murase et al., 1993). Using microelectrodes with resistance ranging from 6 to 8 MΩ were filled with 2 M NaCl and 2% pontamine sky blue dye. The latter was used to confirm the location of recording site within the VTA at the end of each experiment by visual inspection (Fig. 1A, B). The recording electrode was placed into the VTA through a small burr hole (located 3.0 mm anterior to lambda and 0.5–0.9 mm lateral to the midline) and positioned using a stepping motor micromanipulator. DA neurons were usually recorded between 6.5 and 8.5 mm below the cortical surface and identified according to published criteria (Grace and Onn, 1989; Ungless et al., 2004; Zhang et al., 2008), including presence of a long action potential (positive/negative) duration (2–5 ms), a relatively slow firing rate (FR; 1–10 Hz) characterized by an irregular or burst firing pattern, low pitch sounds produced on an audio amplifier, and a 32(36):12366–12375.

Materials and Methods
The protocol for single-unit recording from VTA DA neurons in anesthetized rats was approved by the Institutional Animal Care and Use Committee of the Barrow Neurological Institute.

Single-unit recordings in vivo
VTA neurons. Male Wistar rats (200–220 g) were anesthetized with chloral hydrate (400 mg/kg, i.p., with supplemental doses administered via a lateral tail vein) and mounted in a stereotaxic apparatus (Harvard Apparatus). DA neurons were identified and recorded extracellularly as described previously (Gao et al., 2007, 2011; Zhang et al., 2008). Glass microelectrodes with resistance ranging from 6 to 8 MΩ were filled with 2 M NaCl and 2% pontamine sky blue dye. The latter was used to confirm the location of recording site within the VTA at the end of each experiment by visual inspection (Fig. 1A, B). The recording electrode was placed into the VTA through a small burr hole (located 3.0 mm anterior to lambda and 0.5–0.9 mm lateral to the midline) and positioned using a stepping motor micromanipulator. DA neurons were usually recorded between 6.5 and 8.5 mm below the cortical surface and identified according to published criteria (Grace and Onn, 1989; Ungless et al., 2004; Zhang et al., 2008), including presence of a long action potential (positive/negative) duration (2–5 ms), a relatively slow firing rate (FR; 1–10 Hz) characterized by an irregular or burst firing pattern, low pitch sounds produced on an audio amplifier, and a 32(36):12366–12375.

Drug applications
For systemic nicotine studies, nicotine bitartrate (Sigma-Aldrich) was dissolved in saline to a final concentration of 0.5 mg/ml (all nicotine concentrations refer to the concentration of the salt, but 0.5 mg/ml salt is equivalent to a free base concentration of 0.17 mg/ml). After obtaining a single-unit recording with stable firing for ~5 min, nicotine bitartrate was injected intravenously (0.5 mg/kg, i.v.) through the tail-vein in a volume based on rat body weight and using a regulated syringe pump (Harvard Apparatus). The injection time was set to 30 s. Bicuculline methiodide (BMI; Sigma-Aldrich) was similarly delivered intravenously.

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electrode track</td>
<td>Recording site</td>
<td>Electrode track</td>
<td>Recording site</td>
</tr>
</tbody>
</table>

**Figure 1.** The recording sites of VTA DA neurons and mPFC pyramidal neurons. A, A phase-contrast image illustrates electrode entry and track sites (black arrows) and the general recording site within the VTA (red arrow). B, Schematic diagram of coronal sections through the VTA shows the recording sites of 24 neurons labeled after electrophysiological and pharmacological experimentation. Black dots are type-I neurons (n = 17 from 17 rats), and white circles are type-II neurons (n = 7 from 7 rats). IF, Infralimbic; IL, infralimbic cortex; OFC, orbitofrontal cortex; PL, prelimbic cortex; RN, red nucleus; SN, substantia nigra. C, A phase-contrast image illustrates electrode general recording site within the mPFC (red arrow). D, A coronal section through the rat brain illustrating the mPFC (shaded area). Neurons (n = 6 from 6 rats) were filled in coronal sections at AP, 3.0 mm; ML, 0.7 mm; DV, 3.5 mm from bregma. ACD, Dorsal anterior cingulated cortex; PL, prelimbic cortex; IL, infralimbic cortex; OFC, orbitofrontal cortex.
at a concentration of 2.5 mg/kg. For in situ nicotine experiments, silica capillary tubing (outer diameter, 160 μm; inner diameter, 100 μm) was used to deliver drugs into the mPFC (from bregma, AP, 3.0 mm; ML, 0.7 mm; DV, 3.5 mm). Drugs tested included 10 ng/μl tetrodotoxin (TTX), 100 μM mecamylamine (MEC), or 0.5 μM nicotine in PBS. After a stable baseline recording was established, drugs were infused at 0.75 μl/min for 2 min into both sides of the mPFC (controlled by a syringe pump; Harvard Apparatus). Ten minutes after the infusion, nicotine was injected systemically. Only one cell was recorded per rat. At the end of each experiment, the injection site within the mPFC was verified by visual inspection (Fig. 1 B, C).

Acute PFC transection
To confirm the role of the PFC in nicotine-induced increase of VTA DA neuronal firing, bilateral transections were made immediately caudal to the PFC to interrupt PFC inputs to VTA DA neurons. A slit was drilled in the skull 2.0 mm anterior to bregma. The sharp pointed tip of a 3-mm-wide scalpel blade was lowered to the base of skull and passed along the slit to completely interrupt connections between the PFC and the rest of the brain.

Data analyses
Data were collected and analyzed using a data acquisition system (Fudan University, Shanghai, China) and stored in a computer for offline analysis. All data analyses were performed using programs written in Visual Basic for Applications in Microsoft Excel (Shi et al., 2004). Bursting was identified according to the “80/160 ms” definition proposed by Grace and Bunney, 1984. Firing periodicity was examined using methods similar to those described previously (Shi et al., 2004). Briefly, rate histograms (bandwidth, 50 ms) and autocorrelograms (using an autocovariance function with a bandwidth of 50 ms over 2048 bins) were constructed based on 2 min recordings selected from each cell. After tapering using the Hannings–Tukey window function (15 windows with 50% overlap) and removal of the linear trend, fast Fourier transforms (FFTs) were performed on both the rate histograms and autocorrelograms, yielding spectra with a resolution of 0.078 Hz. Spectra obtained from rate histograms and autocorrelograms were qualitatively identical. The frequency band of 0.5–1.5 Hz was set to determine the power of SOs. We used interstimulus intervals to make autocorrelogram curves, and we used these curves to do FFTs.

Drug effects were determined by comparing measures before and after drug injection, and statistical significance of the comparison between two groups of matched datasets was assessed using two-tailed Student’s t test. Spectral data were log-transformed before being subjected to statistical comparisons. The numerical data were expressed as means ± SEM, and p and t values were presented as the accurate number (unless the number <0.001 was presented as 0.001), and the p values <0.05 were considered significant.

Results
Systemic exposure to nicotine induces biphasic and monophasic firing activity in VTA DA neurons
Of 24 DA neurons tested (from 24 rats), 17 neurons exhibited a biphasic (initial decrease followed by long-lasting increase) change in FR after systemic injection of nicotine (defined as type-I response; Fig. 2 Aa, Ba). The remaining seven neurons had a monophasic increase in FR (defined as type-II response; Fig. 2 Ab, Bb). Additional analysis (using paired t test) showed that, in 17 VTA DA neurons with type-I response, 1 min after systemic administration of nicotine, FR, fraction of bursting (BF), and power of slow oscillations (Pso) were 77.6 ± 5.3% (t16 = 6.49, p < 0.001), 57.9 ± 10.9% (t16 = 3.06, p = 0.007), and 33.3 ± 7.4% (t16 = 5.11, p < 0.001) of baseline levels (Fig. 2 Ca), whereas in seven VTA neurons with type-II response, they were 121.6 ± 4.8% (t6 = −3.13, p = 0.020), 180.3 ± 46.4% (t4 = −1.52, p = 0.20), and 170.7 ± 42.1% of baseline (t6 = −2.13, p = 0.077) (Fig. 2Cb). Five minutes after nicotine administration, the FR, BF, and Pso for the neurons with type-I response (n = 17) were 124.2 ± 7.7% (t16 = −4.71, p < 0.001), 142.2 ± 28.9% (t16 = −2.49, p = 0.024), and 36.2 ± 8.2% (t16 = 5.73, p < 0.001) of baseline levels (Fig. 2 Ca); for the neurons with type-II response (n = 7), they were 108.8 ± 6.1% (t4 = 3.84, p = 0.054), 203.3 ± 60.0% (t4 = 2.36, p = 0.078), and 139.1 ± 32.8% (t6 = −3.15, p = 0.201) of baseline, respectively (Fig. 2Cb). Thus, although nicotine exposure can alter the FR and BF for the VTA DA neurons with both types of responses, the time course for its differential effects across response types on FR is notable, and it has significant and polar opposite effects on Pso between the neurons with type-I and type-II responses.

These results indicate that VTA DA neurons exhibit two types of firing responses based on their differing electrophysiological patterns to systemic exposure to nicotine at a concentration (0.5...
neurons with type-II response exhibited regular spiking (Fig. 3Aa, black line). In contrast, the neurons with type-II response exhibited regular spiking (Fig. 3Ab, gray line). Statistical analyses demonstrated that the baseline values for FR, BF, and Pso in type-I responded DA neurons (n = 17) were 4.5 ± 0.5 Hz, 38.3 ± 7.5%, and 1.7 ± 0.3, whereas in type-II responded DA neurons (n = 7), the baseline values were 4.1 ± 0.8 Hz, 16.1 ± 7.2%, and 0.3 ± 0.1. Statistical comparisons between type-I and type-II responded neurons showed that, although there were no significant differences in their FRs (t(22) = 0.54, p = 0.592), the BF was significantly higher for type-I responded neurons (t(22) = 1.33, p = 0.048), and the values for Pso of the neurons with type-I response were significantly higher than the neurons with type-II response (t(22) = 5.29, p < 0.001) (Fig. 3C). These results again suggest that VTA DA neurons have two types of electrophysiological responses not only to systemic nicotine but also exhibit two types of intrinsic firing patterns and different SO power.

Effects of TTX infusion into the PFC on nicotine-induced firing of VTA DA neurons

Because VTA DA neuron SOs have been found to be an important sign of functional coupling between the PFC and the VTA (Shi, 2005; Gao et al., 2007), we hypothesized that VTA DA neurons with type-I, but not type-II, response to systemic nicotine may be coupled via cortico-meso innervations. To test this, we ablated mPFC–VTA coupling by a local infusion of the sodium channel blocker TTX (10 ng/µl in PBS) bilaterally (0.75 µl/min for 2 min through a syringe pump) into the mPFC (from bregma, AP, 3.0 mm; ML, ± 0.7 mm; DV, 3.5 mm) (Gao et al., 2007). We then examined the effects of systemic nicotine on VTA DA neuron firing. The results showed that local infusion of TTX into the mPFC for 4 min prevented the systemic nicotine-induced excitatory effect on the VTA DA neurons with type-I response (Fig. 4Aa, n = 5) but not the excitatory effect on the neurons with type-II response (Fig. 4Ba, n = 5).

Additional analysis (using paired t test) quantified the effects of systemic nicotine after TTX inhibition of mPFC function. These studies indicated that the effect of systemic nicotine injection on the FR, BF, and Pso (relative to baseline at 100%) for VTA type-I responded neurons was reduced to 74.5 ± 6.1% (t(4) = 3.53, p = 0.024), 37.2 ± 5.4% (t(4) = 2.84, p = 0.047), and 26.1 ± 7.8% (t(4) = 2.09, p = 0.009) when measured 5 min after nicotine exposure (Fig. 4Ab). However, for type-II responded neurons, 5 min after systemic nicotine injection, there still were increases in FR to 144.3 ± 11.5% (t(4) = −3.40, p = 0.027), and no significant effects were observed on BF (148.8 ± 43.6%, t(4) = −1.08, p = 0.341), and Pso (93.2 ± 7.4%, t(4) = −0.03, p = 0.979) (Fig. 4B). These results support the hypothesis that the VTA DA neurons with type-I, rather than type-II, response to nicotine are functionally coupled to the mPFC.

Effects of mPFC–VTA transection on nicotine-induced increases in FR of VTA DA neurons

To complement the preceding experiments, we then bilaterally transected the mPFC immediately caudal to the PFC (2 mm anterior to bregma) (Gao et al., 2007), to physically disconnect mPFC inputs to the VTA DA neurons. Based on our previous experiments involving local TTX application, we predicted that the transection of mPFC inputs (1) should eliminate SOs in the VTA DA neurons with type-I response and (2) would interfere with nicotinic excitation of these neurons but have no effect on the nicotinic excitation in the VTA DA neurons with type-II response.

VTA type-I responded DA neurons (n = 12 from 12 rats) were identified in part because they failed to show the late-phase increase in FR attributable to nicotine injection after transection of mPFC inputs to the VTA (Fig. 5Aa). Presumed type-II responded DA neurons still displayed an increase in FR by nicotine exposure after disruption of mPFC–VTA connections (Fig. 5Ab, n = 6 from 6 rats). When measured 5 min after nicotine exposure (i.e., once responses had stabilized), FR was reduced to 84.9 ± 0.9% in type-I responded DA neurons (t(11) = 4.57, p = 0.001; Fig. 5Ba) but increased to 146.3 ± 13.3% in type-II DA neurons (t(5) = 22.2, p = 0.0001).
Conversely, BF and P in type-I responded neurons were not significantly altered after nicotine exposure ($t_{(11)} = 1.11, p = 0.292; t_{(11)} = 0.176, p = 0.864$), partly because both levels were very low after mPFC transection (Fig. 5Ca,Cb) but consistent with disruption of the otherwise important role for the mPFC in the generation of bursting and SO in a group of DA neurons (Shi, 2005; Gao et al., 2007).

**Effects of local infusion of an nAChR antagonist or agonist into the mPFC on VTA DA neurons with type-I response to systemic nicotine**

Thus far, we have demonstrated that, in the VTA, type-I (but not type-II) responded DA neurons are functionally coupled to the PFC. We further elucidated how systemic nicotine affected VTA DA neurons with type-I response through the alteration of this PFC–VTA coupling. One hypothesis was that systemic nicotine exposure might primarily act on the nAChRs in mPFC neurons, in turn altering PFC–VTA coupling and leading to excitation of these VTA DA neurons. We tested this hypothesis in two experiments.

First, we infused the nAChR antagonist MEC (100 μM, 0.75 μl/2 min) locally into the mPFC and determined the subsequent effects of systemic nicotine injection on VTA type-I responded neuron firing. The results showed that there was no effect of MEC infusion into the PFC alone on FR, BF, or P in VTA type-I responded neurons. However, 4 min of exposure to MEC abolished the systemic nicotine-induced firing increase in these neurons (Fig. 6Aa). In nine VTA DA neurons with type-I response, after local infusion of MEC into the mPFC, systemic nicotine-induced alterations in FR, BF, and SO were $98.8 \pm 3.7\% (t_{(8)} = 0.07, p = 0.949), 114.8 \pm 11.4\% (t_{(8)} = -1.36, p = 0.211),$ and $160.4 \pm 23.5\% (t_{(8)} = -1.05, p = 0.327)$ of baseline levels when measured 5 min later (Fig. 6Ab). These results implicated a role for nAChRs in the mPFC and of mPFC–VTA coupling in this group of VTA DA neurons.

Second, we locally infused nicotine itself (0.5 μM, 0.75 μl/2 min) into the mPFC, and, 1 or 5 min later, we examined its effects on VTA type-I responded neuron firing. There was no effect on neuronal FR measured 1 or 5 min after local infusion of nicotine into the mPFC (Fig. 6B, n = 6, $t_{(5)} = 0.99, p = 0.365$ vs baseline). However, additional analysis showed a significant increase in P in these neurons (Fig. 6Bb, $t_{(3)} = -2.74, p = 0.041$). These experiments suggest that local infusion of nicotine into the mPFC increases mPFC descending coupling to VTA DA neurons with type-I response to systemic nicotine, as exemplified by increased P. However, this method of nicotine administration (0.5 mg/kg nicotine bitartrate) is insufficient to mimic all of the effects of systemic nicotine on VTA type-I DA neuron firing, suggesting that additional target sites might be involved in systemic nicotine-induced excitation of VTA DA neurons, although actions in the mPFC might gate such effects.

**Systemic injection of nicotine acutely increases mPFC pyramidal neuron firing**

To test the hypothesis that systemic nicotine can act on mPFC nAChRs to excite mPFC pyramidal neurons, we recorded mPFC pyramidal neuron firing after systemic nicotine injection. Nicotine (0.5 mg/kg, i.v.) induced a biphasic change in FR, BF, and P (initial increase followed by long-lasting decrease) of mPFC pyramidal neurons (Fig. 7, n = 6), which interestingly is the inverse of the pattern observed for nicotine-induced changes in the FR for VTA DA neurons with type-I response (Fig. 2Ba).

Statistical analyses (using paired t test) showed that, after the injection of nicotine, the FR, BF, and P were 225.0 ± 45.6%, ($t_{(5)} = -2.95, p = 0.032$), 109.2 ± 3.8%, ($t_{(5)} = -2.75, p = 0.040$), and 221.5 ± 34.3%, ($t_{(5)} = -2.01, p = 0.021$) of baseline levels in mPFC pyramidal neurons when measured 1 min after nicotine injection but were 60.8 ± 4.0% ($t_{(5)} = 2.535, p = 0.048$), 80.5 ± 6.7% ($t_{(5)} = 2.87, p = 0.035$), and 34.6 ± 15.2% ($t_{(5)} = 2.76, p = 0.008$) of baseline levels when measured 5 min afternicotine injection (Fig. 7C).

These results provide direct evidence that systemic nicotine rapidly and significantly excites mPFC pyramidal neuronal firing, bursting activity, and SO, but these effects do not persist and, in fact, reverse 5 min after nicotine administration.

**Effects of BMI on the nicotine-induced increase in the VTA DA neurons with type-I response to nicotine**

The apparent inverse relationship between firing patterns of mPFC and VTA DA neurons (with type-I response) suggested...
that there may be an intervening, inhibitory connection, likely involving GABA, in the descending mPFC–VTA pathway (Gao et al., 2007). To test this possibility, we systemically injected the GABA receptor antagonist BMI (2.5 mg/kg, i.v.) and then evaluated nicotine-induced effects on both mPFC pyramidal neurons and VTA type-I DA neurons.

There was no change in baseline firing of mPFC pyramidal neurons (n = 6) in rats exposed to BMI (Fig. 8Aa). However, subsequent systemic administration of nicotine still excited mPFC neurons as reflected in the significant increase measured 1 min after nicotine exposure relative to baseline levels in FR (160.2 ± 30.3%, t(5) = −4.07, p = 0.009), BF (150.2 ± 15.1%, t(5) = −3.37, p = 0.014), and Pso (149.2 ± 35.3%, t(5) = −2.08, p = 0.009; Fig. 8Ab). However, BMI preexposure did abolish the nicotine-induced late-phase reduction in mPFC neuron firing, otherwise (Fig. 7) seen 5 min after nicotine injection (FR = 60.8 ± 4.0% of baseline, t(5) = 2.54, p = 0.048 for nicotine alone and FR = 101.8 ± 11.0% for nicotine after BMI injection, t(5) = −1.76, p = 0.139, n = 6; Fig. 8Ab).

We next determined the effects of BMI preexposure on nicotine-induced effects on type-I responded VTA DA neurons (n = 6 from 6 rats). The results show that, although BMI exposure did not alter the FR and BF, it did diminish Pso significantly (Fig. 8Bb). Statistical analysis showed that, in six VTA type-I responded DA neurons tested after BMI treatment, nicotine-induced alterations in FR, BF, and Pso were 96.0 ± 5.0% (t(5) = 0.78, p = 0.47), 92.4 ± 9.4% (t(5) = 0.99, p = 0.37), and 69.3 ± 4.2% (t(5) = 1.86, p = 0.007) of baseline levels when measured 1 min after nicotine injection, and they were 97.9 ± 7.5% (t(5) = 0.56, p = 0.597), 107.9 ± 10.2% (t(5) = −0.23, p = 0.824), and 70.1 ± 3.8% (t(5) = 1.75, p = 0.005; p = 0.974 compared with the baseline after BMI) when measured 5 min after nicotine injection. This indicates that BMI eliminates SO and both the early inhibitory and the late excitatory effects of systemic nicotine on the VTA DA neurons with type-I response.

These results also are consistent with the hypothesis that systemic nicotine exposure has its effects on VTA type-I responded DA neuronal firing by altering the activity of mPFC neurons, which ordinarily are inversely coupled to those VTA DA neurons through intervening GABAergic synapses.

Discussion

The release of DA into the NAc and the mPFC after the excitation of VTA DA neurons is considered to be an important mechanism underlying drug reward and addiction (Wise, 2004). Patch-clamp recordings in VTA slices have shown that nicotine at concentrations comparable with those found in human cigarette smokers excites VTA DA neurons (Pidoplichko et al., 1997). Nicotine also induced desensitization of α4β2–nAChRs on GABAergic neurons in the VTA, thereby reducing endogenous cholinergic excitation of those neurons and release of GABA onto DA neurons, which thus become disinhibited (Pidoplichko et al., 1997, 2004; Mansvelder et al., 2002).

However, systemic administration of nicotine affects the activity of DA neurons through mechanisms that are more complex, involving the VTA and other brain regions (Mameli-Engvall et al., 2006; Avale et al., 2008), such as the mPFC (Erhardt et al., 2002; Ikemoto et al., 2006). Several studies have consistently shown a functional coupling between the mPFC and the VTA. For example, stimulation of the mPFC increases burst firing in VTA DA neurons, whereas inactivating the mPFC decreases VTA DA neuronal activity (Gariano and Groves, 1988; Svensson and Tung, 1989; Murase et al., 1993; Overton et al., 1996a; Tong et al., 1996). In addition, mPFC-induced increase in DA neuronal bursting is often preceded by an inhibition of DA neuronal firing that lasts up to several hundred milliseconds (Nakamura et al., 1979; Thierry et al., 1979; Gariano and Groves, 1988; Overton et al., 1996b; Tong et al., 1996; Overton and Clark, 1997), suggesting that initial excitation of mPFC neurons inhibits VTA DA neurons...
via activation of inhibitory GABAergic neurons. Furthermore, stimulating mPFC excites VTA GABAergic neurons in either a monophasic or biphasic pattern (Geisler and Wise, 2008). More importantly, the mPFC produces a relatively long-lasting GABAergic inhibitory action on VTA DA neurons, which is thought to underlie disinhibition-induced DA neuron excitation, especially during exposure to addictive drugs (Tong et al., 1996). We previously reported a covariance of spontaneous activity of VTA DA neurons and mPFC neurons suggestive of functional coupling (Gao et al., 2007). However, simultaneous dual-field potential recordings demonstrated that field SOs in the mPFC preceded those in the VTA by ~30 ms, and transection of, or local injection of TTX into, the mPFC abolished VTA neuronal SOs. Together, this suggests a negative coupling between mPFC and VTA DA neurons (Gao et al., 2007). Finally, pharmacological MRI studies also showed that systemic nicotine exposure in humans caused a prominent increase in cerebral blood flow to the mPFC and the VTA (Choi et al., 2006; Gozzi et al., 2006), consistent with the concept that mPFC–VTA (Choi et al., 2006; Gozzi et al., 2006), cerebral blood flow to the mPFC and the VTA. This idea is consistent with the dual-field potential recordings in the PFC and the VTA that display highly synchronized SOs between mPFC and the VTA (Peters et al., 2004).

VTA DA neurons exhibit two types of spiking profiles in response to systemic nicotine. The high P\textsubscript{SO} only seen in the neurons with type-I response, and the inverse relationships between the changes of their FRs and the FRs of mPFC neurons after nicotine exposure, provide clear indications of mPFC–VTA negative coupling, as well as a useful means for identifying those cells experimentally. The new findings based on pharmacological disruption or a physical severance of connections to the mPFC underscore their pivotal role in mPFC mediation of nicotine-induced excitation of those VTA DA neurons with type-I response. Whether or not these VTA DA neurons with differential responses to nicotine are correlated to a defined subgroup of DA neurons in the VTA (based on neuronal locations, projections, or response to reward/aversive stimulations) are unclear. It will be highly interesting to evaluate this in a future study.

Systemic nicotine administration significantly reduces P\textsubscript{SO} in type-I responded DA neurons while increasing their FR. This is consistent with nicotine acting to functionally uncouple the mPFC–VTA circuit. BMI exposure also lowers P\textsubscript{SO} and completely blocks initial inhibitory and late excitatory effects of nicotine on the VTA DA neurons with type-I response. This is consistent with nicotine having its effects and with mPFC–VTA DA neuronal inverse coupling being mediated via an inhibitory, GABAergic mechanism. It has been reported that GABAergic neurons in the VTA exhibit oscillations at 1–2 Hz (Steffensen et al., 1998) and that VTA GABAergic neurons receive glutamatergic innervations from the PFC (Carr and Sesack, 2000; Geisler and Wise, 2008). These GABAergic neurons may play a role in the transfer of SOs from mPFC to the VTA neurons with type-I response. A role for mPFC nAChRs in the excitatory response of these DA neurons to nicotine is evident from the sensitivity of that response to MEC applied locally into the mPFC. Moreover, the ability of BMI administration to prevent the late inhibitory phase of the actions of nicotine on mPFC neuronal firing suggests that GABA\textsubscript{A} receptors, at least partly, mediate that effect. However, the insensitivity to BMI of the initial, excitatory effect of nicotine exposure on mPFC neuronal firing is consistent with an effect via nAChR-mediated activation of presynaptic glutamate release in the mPFC (Dickinson et al., 2008; Konradsson-Geuken et al., 2009; Livingstone et al., 2009), but this idea requires additional investigation. These results suggest that the nicotine-induced initial inhibition on the DA neurons with type-I response may be mediated by GABAergic neurons that may not be controlled by the PFC.

In the mPFC, nicotine exposure culminates in a delayed but longer-lasting reduction in mPFC neuronal firing, likely through activation of GABAergic mechanisms (Aracri et al., 2010). Such a process, which would lead to lasting activation of VTA DA neurons, has been implicated in morphine-, muscimol-, and benzodiazepine-induced VTA DA neuron excitation (Gysling and Wang, 1983; Lokwan et al., 2000). However, our studies suggest that consideration should be given to the nicotine exposure-induced impairment of inverse coupling between the mPFC and the VTA via the GABAergic neurons as defined by...
diminished $P_{SO}$ as a novel, alternate mechanism for nicotine-induced DA neuron excitation in vivo.

The major feature of drug addiction is a reduced ability to regulate control over the desire to procure drugs regardless of the risks involved. Traditional models implicated the neural “reward” (i.e., VTA) system as the key brain region in providing a neurobiological model of addiction. Computational models of the local VTA circuitry suggested that a biphasic pattern of response to nicotine could be mediated by nicotine action on the nAChRs at local GABAergic neurons and subsequent disinhibition of the DA neurons (Ahmed et al., 2009; Graupner and Gutkin, 2009). However, ideas that are more recent have expanded on this circuitry to include two separate but interconnecting systems: the VTA in the incentive sensitization of drugs, and the PFC in regulating inhibitory control over drug use.

The neurophysiological results we show here provide experimental evidence to support this new model. This is particularly significant when put into the larger context of drug addiction theory. The development of drug addiction has been likened to a progressive habitualization of behavior and a loss of cognitive control (Everitt and Robbins, 2005; Feil et al., 2010), possibly through a disconnection of higher cortical influence over reward circuitry (Kalivas, 2009). Consistent with the notion that the mPFC plays a role in drug addiction through the modulation of descending inhibitory system (Feil et al., 2010) and in line with the concept that the mPFC mediates cognitive control (executive functions), the inverse coupling that we show here suggests that the mPFC exerts this control through multisynaptic gating of inhibition and excitation of DA transmission and that nicotine selectively disrupts this inhibitory control, leading to a dysfunctional modulation of the VTA DA neurons with type-I response.

Furthermore, recent computational theories propose an opposition of cognitive control versus reward-driven habitual action (Daw et al., 2005), suggesting that a model-based cortical system can ensure flexible achievement of long-term goals, whereas a model-free, reward-based, DA system promotes habitual seeking of immediate rewards. The theory proposes that an optimal integration between the two systems for control of behavior is the key and may be mediated by cholinergic signals encoding the uncertainty of the behavioral context (Yu and Dayan, 2005). Thus, we speculate that nicotine would pathologically remove the influence of the cortical model-based cognitive control system over the DA circuitry and promote habitual immediate-reward-
seeking behavior. Our results, by pointing to a nicotine-induced uncoupling of the mPFC-mediated inhibited control over reward circuitry, provide a potential neural basis for the bias toward impulsivity and loss of cognitive control seen in nicotine-dependent individuals and possibly other types of drug dependencies.

References


Ikemoto S, Qin M, Liu ZH (2006) Primary reinforcing effects of nicotine are triggered from multiple regions both inside and outside the ventral tegmental area. J Neurosci 26:723–730.


Zhang et al. • Prefrontal Cortical Up States and Ventral Tegmental Oscillations J. Neurosci., September 5, 2012 • 32(36):12366–12375 • 12375